DiagnOptics – AGE Reader®


Established in 2003, DiagnOptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader® - a state of art diagnostic device which can determine the tissue accumulation of AGEs in 30 seconds.

AGE Reader®

AGE Reader®

The AGE Reader® provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes, cardiovascular disease and renal failure. The AGE Reader® yields a real time and non-invasive assessment of cardiovascular risk. The method is convenient, easy to use and validated. The AGE Reader® measures tissue accumulation of Advanced Glycation Endproducts (AGEs) by means of fluorescence techniques - skin autofluorescence (skin AF). AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes, cardiovascular disease and renal failure.


The AGE Reader® has a light source which illuminates the skin of the forearm. This light will excite fluorescent moieties in the tissue which will emit light of a different wavelength. In the used wavelength band the major contribution in fluorescence comes from fluorescent AGEs linked mostly to collagen, but also to other proteins and lipids. The emitted light is detected using a spectrometer.

Clinical Validation

The comfortable and safe AGE Reader® measurement offers crucial clinical information to clinicians and researchers. The AGE Reader® has been validated against the gold standard for measuring AGEs (skin biopsies). It was shown that skin AF is strongly correlated with AGEs.

The device has been clinically validated in multiple large-scale, clinical trials over the last few years involving tens of thousands of healthy controls, diabetics, cardiovascular and renal patients. The clinical studies demonstrate that skin auto-fluorescence is a strong and independent risk predictor for mortality and cardiovascular events. In particular, it can independently predict cardiovascular co-morbidity and mortality in diabetes, renal failure and dialysis patients.

Clinical Value

The information from the AGE Reader® can assist physicians in focusing treatment on patients with the highest risk of complications. This includes patients suffering from diabetes mellitus, renal failure but also acute disorders like acute coronary syndromes and sepsis. Moreover it is an excellent tool for researchers in various fields.


  • Patient management
    • Assessment of cardiovascular risk
    • Identifying patients at high risk
    • End point for measuring treatment response
    • Improving targeted cost effective treatment plan Clinical studies
  • Clinical studies
    • Studies on diabetes
    • Studies on renal failure and cardiovascular disease
    • Studies on other AGE related conditions
  • Treatment selection and monitoring
    • Identify good drug responders
    • Pharmaceutical evaluation
    • Intensive care patient monitoring
    • Dialysis patient and renal transplant monitoring Scientific research
  • Scientific research
    • Nutritional research
    • Aging research
    • Skin care research
  • New drug development
    • Inhibition of AGE formation
    • AGE breakers and blockers
    • New drug evaluation
  • Public screening
    • Identify undiagnosed diabetic patients
    • Identify individuals with high cardiovascular risk
    • Professional health assessment